Hansa Biopharmas Idefirix Receives European Approval For Highly Sensitized Kidney Transplants Patients

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, announced that the European Commission has granted conditional approval for Idefirix in highly sensitized kidney transplants patients.The formal approval by the European Commission was received two months after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending conditional approval of Idefirix for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor."We are very excited about this decision from the European Commision to approve Idefirix in highly sensitized kidney transplant patients. This is the first approved drug for HansaBiopharma and will bring hope to the thousands of highly sensitized patients across Europe waiting for a life-saving kidney transplant" says SørenTulstrup, president & CEO of Hansa Biopharma."This approval further serves as a validation of the potential of Hansa Biopharma's proprietary drug development engine and will transform the company into a commercial stage biopharmaceutical company that brings lifesaving and life altering therapies to patients with rare diseases who need them and generate value to society at large."Idefirix has been reviewed as part of the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) programs, which support medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options.The first treatment with Idefirix is expected to be available to patients in select European countries during the fourth quarter 2020, as communicated earlier. A post-approval study will be initiated in parallel with the launch following the market authorization.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!